2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2568 Analytical validation of a targeted hybridization-capture sequencing panel for genomic characterization of enriched circulating multiple myeloma cells

Steven Mark Jones, Thomas Hansen2, Frank Kuhr3, Wojciech Swat, PhD4, Zoltan Simandi5
1 Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania, United States
2 Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania, United States
3 Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania, United States
4 Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania, United States
5 Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania, United States
Background

Genomic profiling of circulating multiple myeloma cells (CMMCs) offers a minimally invasive alternative to bone marrow biopsies in multiple myeloma, yet molecular characterization from low-input, immunomagnetically enriched cell pools lacks standard analytical validation. Bridging this gap requires establishing performance metrics for multi-variant profiling from minimally-invasive peripheral blood specimens. Here, we report the analytical validation of a targeted hybridization-capture sequencing panel evaluating single-nucleotide variants (SNVs), small insertions/deletions (indels), copy-number alterations (CNAs), and immunoglobulin heavy-chain rearrangements from enriched pools of CMMCs.

Methods

Analytical validation was conducted across 141 specimens in seven experimental arms, including within-laboratory precision, inter-day repeatability, accuracy, a cellular dilution series, an in-silico read-depth series, 23 clinical multiple myeloma (MM) specimens, and 12 healthy donor controls. Assessable regions spanned essential myeloma coding exons, targeted copy-number genomic footprints across canonical disease loci, and immunoglobulin heavy-chain framework regions. Calls were generated via a locked bioinformatic pipeline for variant merging, CNA segmentation, and structural variant (SV) calling.

Results

Analytical validation met all pre-specified criteria. Within-operator mean allele-fraction coefficient of variation (CV) was 9.9-11.0%, inter-operator CV was 10.8%, and inter-day CV was 11.5% (varying from 1.0-3.0% at high allele fractions to 10.6-18.3% at low fractions). CNA segment dispersion ranged from 0.045–0.116. Expected SV events were detected in 100% of comparison replicates. Sequence-variant concordance with multi-source reference genotypes was 18 of 18 (100%; 95% CI 82.4-100.0%). Target detection was maintained down to 40–100% target-cell fractions. Process blanks yielded zero false-positive locus, CNA, or SV calls. In depth-series modeling, sequence detection persisted down to 23-fold coverage. Analytical specificity in healthy donors was 0.9988 for CNA (1 false call in 840 opportunities) and 1.0000 for SVs (0 in 528); SNV specificity was 0.926 (per assessable gene) or 0.99998 (per assessable base) after removing catalogued common germline variants. Co-occurring TP53 copy loss and sequence variants were detected in 5 of 5 specimens with loss, with independent confirmation by secondary chromosomal arm targets. Canonical immunoglobulin rearrangements were identified in 7 clinical specimens. Additionally, across the other locus-specimen opportunities, spanning known immunotherapy antigen-encoding loci (TNFRSF17, GPRC5D, CD38, FCRL5, SLAMF7), non-neutral copy states were detected, with regional or focal copy loss identified in 8 of 23 clinical specimens.

Conclusions

Targeted genomic profiling of enriched CMMCs provides precise, reproducible detection of SNVs, indels, CNAs, and SVs from peripheral blood. Crucially, the assay enables minimally invasive characterization of high-risk TP53 alterations alongside copy-state alterations at loci encoding key targets of BCMA, GPRC5D, FCRL5 and CD38-directed immunotherapies, demonstrating clinical applicability for multi-class genomic profiling, with potential to inform targeted treatment selection from routine liquid biopsy inputs.

Zoltan Simandi: Menarini Silicon Biosystems - Current Employment